Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/BCL2L1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/BCL2L1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BCL2L1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/BCL2L1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BCL2L1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/BCL2L1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BCL2L1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BCL2L1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19054763 | Liver | Cirrhotic | negative regulation of protein localization to membrane | 17/4634 | 32/18723 | 5.24e-04 | 4.14e-03 | 17 |
GO:00432002 | Liver | Cirrhotic | response to amino acid | 45/4634 | 116/18723 | 5.54e-04 | 4.36e-03 | 45 |
GO:00009105 | Liver | Cirrhotic | cytokinesis | 62/4634 | 173/18723 | 7.13e-04 | 5.33e-03 | 62 |
GO:200102011 | Liver | Cirrhotic | regulation of response to DNA damage stimulus | 75/4634 | 219/18723 | 9.75e-04 | 6.89e-03 | 75 |
GO:19020424 | Liver | Cirrhotic | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 16/4634 | 31/18723 | 1.15e-03 | 7.83e-03 | 16 |
GO:19043764 | Liver | Cirrhotic | negative regulation of protein localization to cell periphery | 14/4634 | 26/18723 | 1.37e-03 | 9.14e-03 | 14 |
GO:009728411 | Liver | Cirrhotic | hepatocyte apoptotic process | 10/4634 | 16/18723 | 1.51e-03 | 9.91e-03 | 10 |
GO:1903317 | Liver | Cirrhotic | regulation of protein maturation | 28/4634 | 67/18723 | 1.60e-03 | 1.04e-02 | 28 |
GO:00108236 | Liver | Cirrhotic | negative regulation of mitochondrion organization | 22/4634 | 49/18723 | 1.64e-03 | 1.05e-02 | 22 |
GO:001021211 | Liver | Cirrhotic | response to ionizing radiation | 53/4634 | 148/18723 | 1.70e-03 | 1.08e-02 | 53 |
GO:00518815 | Liver | Cirrhotic | regulation of mitochondrial membrane potential | 30/4634 | 74/18723 | 1.97e-03 | 1.23e-02 | 30 |
GO:00614585 | Liver | Cirrhotic | reproductive system development | 132/4634 | 427/18723 | 2.07e-03 | 1.28e-02 | 132 |
GO:00486085 | Liver | Cirrhotic | reproductive structure development | 131/4634 | 424/18723 | 2.19e-03 | 1.34e-02 | 131 |
GO:00069191 | Liver | Cirrhotic | activation of cysteine-type endopeptidase activity involved in apoptotic process | 31/4634 | 78/18723 | 2.43e-03 | 1.46e-02 | 31 |
GO:19040191 | Liver | Cirrhotic | epithelial cell apoptotic process | 44/4634 | 121/18723 | 2.86e-03 | 1.65e-02 | 44 |
GO:00435242 | Liver | Cirrhotic | negative regulation of neuron apoptotic process | 51/4634 | 145/18723 | 3.15e-03 | 1.78e-02 | 51 |
GO:19022367 | Liver | Cirrhotic | negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 11/4634 | 20/18723 | 3.61e-03 | 1.99e-02 | 11 |
GO:0071229 | Liver | Cirrhotic | cellular response to acid chemical | 31/4634 | 80/18723 | 3.83e-03 | 2.10e-02 | 31 |
GO:0070613 | Liver | Cirrhotic | regulation of protein processing | 26/4634 | 65/18723 | 4.73e-03 | 2.48e-02 | 26 |
GO:00018366 | Liver | Cirrhotic | release of cytochrome c from mitochondria | 24/4634 | 59/18723 | 5.06e-03 | 2.62e-02 | 24 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa05220 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
hsa05225 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa04137 | Colorectum | AD | Mitophagy - animal | 29/2092 | 72/8465 | 2.49e-03 | 1.35e-02 | 8.59e-03 | 29 |
hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa01521 | Colorectum | AD | EGFR tyrosine kinase inhibitor resistance | 29/2092 | 79/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 29 |
hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa054171 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa051701 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa052201 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
hsa052251 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa041371 | Colorectum | AD | Mitophagy - animal | 29/2092 | 72/8465 | 2.49e-03 | 1.35e-02 | 8.59e-03 | 29 |
hsa051661 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa015211 | Colorectum | AD | EGFR tyrosine kinase inhibitor resistance | 29/2092 | 79/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 29 |
hsa050124 | Colorectum | MSS | Parkinson disease | 140/1875 | 266/8465 | 2.32e-28 | 7.79e-26 | 4.77e-26 | 140 |
hsa050224 | Colorectum | MSS | Pathways of neurodegeneration - multiple diseases | 192/1875 | 476/8465 | 2.79e-20 | 1.04e-18 | 6.36e-19 | 192 |
hsa050144 | Colorectum | MSS | Amyotrophic lateral sclerosis | 156/1875 | 364/8465 | 1.43e-19 | 4.62e-18 | 2.83e-18 | 156 |
hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Indole-based analog 2 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | NAVITOCLAX, ABT-263 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | antagonist | 252166532 | ABT 737 | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | PMID27744724-Compound-26 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | GOSSYPOL | GOSSYPOL | 19555126 |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | antagonist | 252166530 | VENETOCLAX | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | APG-1252 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ABT-737 | ABT 737 | 22386982,22747598 |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ABT-263 | NAVITOCLAX | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | CHEMBL443684 | NAVITOCLAX | |